Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Current Treatment Options in Neurology

Volumn 12, Issue 2, 2010, Pages 84-94

  Robertson, Eliza E ^a   Donofrio, Peter D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RITUXIMAB;

ALOPECIA; ANEMIA; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; ASTHENIA; BLADDER DISEASE; BONE MARROW SUPPRESSION; CATARACT; CELLULAR IMMUNITY; CHILOMASTIX; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONSTIPATION; DEMYELINATION; DEPRESSION; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EUPHORIA; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFERTILITY; INSOMNIA; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MENTAL DISEASE; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELITIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PERFORATION; PERIPHERAL EDEMA; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RASH; REVIEW; SEPSIS; SIDE EFFECT; STROKE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TREMOR; VIRUS INFECTION; VOMITING; WEIGHT GAIN; WOUND HEALING;

EID: 77953542254     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0058-9     Document Type: Review

References (39)

1. Merkies ISJ, Bril V, Dalakas MC, et al.: Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. The ICE Study. Neurology 2009, 72:1337-1344.
2. McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987, 110(Pt 6):1617-1630.
3. Ruts L, van Konigsveld R, van Doorn PA: Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology 2004, 65(1):138-140.
4. Gorson KC: Chronic inflammatory demyelinating polyradiculoneuropathy. AANEM 2009 Course B, Dysimmune Neuropathies. American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 56th Annual Meeting. San Diego, CA; October 7-10, 2009. This article, which is published as a section of the AANEM 2009 course in the Dysimmune Neuropathies, provides a comprehensive review of CIDP, including clinical features, clinical variants, concurrent diseases, laboratory evaluation, electrodiagnostic criteria, pathology, differential diagnosis, and treatment.
5. Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. New England Journal of Medicine 2005, 352:1343-1356.
6. Amato AA, Russell JA: Neuromuscular Disorders, New York: McGraw-Hill; 2008:233-260.
7. Austin JH: Recurrent polyneuropathies and their corticosteroid treatment; with five year observations of a placebo-controlled case treated with corticotrophin, cortisone and prednisone. Brain 1958, 81(2):157-192.
8. Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2002, (1):CD002062. Review.
9. Kuitwaard K, van Doorn PA: Newer therapeutic options for chronic inflammatory polyradiculoneuropathy. Drugs 2009, 69(8):987-1001.
10. Leger J, Chassandre B, Musset L, et al.: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124:145-153.
11. Nobile-Orazio E, Meucci N, Baldini L, et al.: Long term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123(Pt 4):710-717.
12. Koski CL, Baumgarten M, Magder LS, et al.: Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. Journal of the neurological sciences 2009, 277:1-8. These new diagnostic criteria for CIDP, developed by an international expert committee, have demonstrated higher sensitivity and specificity than all previously published criteria.
13. Rajabally YA, Jacob S, Hbahbih M: Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. Journal of the Peripheral Nervous System 2005, 10:282-292.
14. Dyck PJ, LitchyWJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 1994, 36(6):838-845.
15. Hughes R, Bensa S, Willison H, et al.: Inflammatory Neuropathy Cause and Treatment (INCAT) Group: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 2001, 50 (2):195-201.
16. Dyck PJ, O'Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Annals of Neurology 1982, 11(2):136-141.
17. Muley SA, Kelkar P, Parry GJ: Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Archives of Neurology 2008, 65 (11):1460-1464.
18. Lopate G, Pestronk A, Al-Lozi M: Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Archives of Neurology 2005, 62 (2):249-254.
19. Hughes RA, Donofrio P, Bril V, et al.: on behalf of the ICE Study Group: Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo controlled trial. Lancet Neurology 2008, 7:136-144. This is the publication of the findings of the ICE Study, the largest randomized placebo-controlled trial for any CIDP treatment, showing efficacy of IVIG (10% caprylate-chromatography purified) over placebo
20. Donofrio PD, Berger A, Brannagan TH 3rd, et al.: Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions. Report of the AANEM ad hoc committee. Muscle Nerve 2009, 40(5):890-900.
21. Eftimov F, Winer JB, Vermeulen M, et al.: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2009 Jan 21, (1):CD001797. Review.
22. Hughes RA: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev Neurother 2009, 9(6):789-795.
23. Brannagan TH 3rd: Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immunemediated neuropathies [review]. Neurology 2002, 59 (12 Suppl 6):S33-S40.
24. Dyck PJ, Daube J, O'Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. New England Journal of Medicine 1986, 314(8):461-465.
25. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, shamcontrolled, cross-over study. Brain 1996, 119(Pt 4):1055-1066.
26. Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004, (3):CD003906. Review.
27. Hahn AF, Bolton CF, Zochodne D, et al.: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a doubleblind, placebo-controlled, cross-over study. Brain 1996, 119(Pt 4):1067-1077.
28. Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004 Oct 18, (4): CD003280. Review.
29. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715-717.
30. Meriggioli MN, Rowin J: Chronic inflammatory demyelinating polyneuropathy after treatment with interferon alpha. Muscle Nerve 2000, 23:433-435.
31. Gorson KC, Ropper AH, Clark BD, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998, 50:84-87.
32. Pavesi G, Cattaneo L, Marbini A, et al.: Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 2002, 249:777-779.
33. Briani C, Zara G, Zambello R, et al.: Rituximabresponsive CIDP. European Journal of Neurology 2004, 11(11):788.
34. Knecht H, Baumberger M, Tobon A, Steck A: Sustained remission of CIDP associated with Evans syndrome. Neurology 2004, 63:730-732.
35. Chin RL, Sherman WH, Sander HW, et al.: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences 2003, 210(1-2):19-21.
36. Kazmi MA, Mahdi-Rogers M, Sanvito L: Chronic inflammatory demyelinating polyradiculoneuropathy: A role for haematopoietic stem cell transplantation? Autoimmunity 2008, 41(8):611-615.
37. Mahdi-Rogers M, KazmiM, Ferner R, et al.: Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. Journal of the Peripheral Nervous System 2009, 14(2):118-124.
38. Gladstone DE, Prestrud AA, Brannagan TH 3rd: High-dose cyclophosphamide results in long-term remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System 2005, 10 (1):11-16.
39. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991 May, 41(5):617-618. Review.